Sweden
· Delayed Price · Currency is SEK Immunovia AB Statistics
Total Valuation
Immunovia AB has a market cap or net worth of SEK 105.90 million. The enterprise value is 68.35 million.
| Market Cap | 105.90M |
| Enterprise Value | 68.35M |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovia AB has 306.08 million shares outstanding. The number of shares has increased by 195.20% in one year.
| Current Share Class | 306.08M |
| Shares Outstanding | 306.08M |
| Shares Change (YoY) | +195.20% |
| Shares Change (QoQ) | +54.33% |
| Owned by Insiders (%) | 6.89% |
| Owned by Institutions (%) | 15.18% |
| Float | 284.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 200.58 |
| PB Ratio | 3.62 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.52 |
| EV / Sales | 129.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.00.
| Current Ratio | 2.84 |
| Quick Ratio | 2.84 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financial Efficiency
Return on equity (ROE) is -360.19% and return on invested capital (ROIC) is -160.22%.
| Return on Equity (ROE) | -360.19% |
| Return on Assets (ROA) | -114.24% |
| Return on Invested Capital (ROIC) | -160.22% |
| Return on Capital Employed (ROCE) | -358.60% |
| Revenue Per Employee | 58,667 |
| Profits Per Employee | -14.60M |
| Employee Count | 9 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.24% in the last 52 weeks. The beta is 2.69, so Immunovia AB's price volatility has been higher than the market average.
| Beta (5Y) | 2.69 |
| 52-Week Price Change | -77.24% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.64 |
| Relative Strength Index (RSI) | 54.45 |
| Average Volume (20 Days) | 4,563,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Immunovia AB had revenue of SEK 528,000 and -131.39 million in losses. Loss per share was -1.04.
| Revenue | 528,000 |
| Gross Profit | 528,000 |
| Operating Income | -104.92M |
| Pretax Income | -131.39M |
| Net Income | -131.39M |
| EBITDA | -90.71M |
| EBIT | -104.92M |
| Loss Per Share | -1.04 |
Balance Sheet
The company has 37.67 million in cash and 110,000 in debt, giving a net cash position of 37.56 million or 0.12 per share.
| Cash & Cash Equivalents | 37.67M |
| Total Debt | 110,000 |
| Net Cash | 37.56M |
| Net Cash Per Share | 0.12 |
| Equity (Book Value) | 29.26M |
| Book Value Per Share | 0.12 |
| Working Capital | 26.77M |
Cash Flow
| Operating Cash Flow | -96.70M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -19,871.78% |
| Pretax Margin | -24,883.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovia AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -195.20% |
| Shareholder Yield | -195.20% |
| Earnings Yield | -124.06% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |